005690.KS
Pharmicell Co., Ltd. [005690.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
005690.KS Stock Summary
Top 005690.KS Correlated Resources
005690.KS
Top 10 Correlated ETFs
005690.KS
Top 10 Correlated Stocks
005690.KS
In the News
005690.KS Financial details
Company Rating
Buy
Market Cap
622.24B
Income
12.91B
Revenue
60.05B
Book val./share
1383.54
Cash/share
477.38
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
06 Feb 2023
P/E
48.95
Forward P/E
-
PEG
3.32
P/S
10.52
P/B
7.66
P/C
22.2
P/FCF
-27.33
Quick Ratio
1.14
Current Ratio
2.67
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
215.2
EPS next Y
-
EPS next Q
-
EPS this Y
82.41%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
15.1%
Revenue Q/Q
27.13%
EPS Q/Q
75.68%
-
-
-
-
SMA20
-5.37%
SMA50
0.45%
SMA100
-14.82%
Inst Own
-
Inst Trans
-
ROA
11%
ROE
17%
ROC
0.1%
Gross Margin
42%
Oper. Margin
15%
Profit Margin
21%
Payout
-
Shs Outstand
60M
Shs Float
39.8M
-
-
-
-
Target Price
-
52W Range
8570.0-16450.0
52W High
-35.56%
52W Low
+23.69%
RSI
51.29
Rel Volume
0.38
Avg Volume
450.05K
Volume
172.66K
Perf Week
3.92%
Perf Month
-7.83%
Perf Quarter
-22.34%
Perf Half Y
-9.01%
-
-
-
-
Beta
-0.811703
-
-
Volatility
137.81%, 472.42%
Prev Close
-0.93%
Price
10600
Change
-1.4%
005690.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 431.52 | 477.57 | 541.85 | 629.77 | 848.99 | |
| Net income per share | -671.27 | -213.6 | 72.52 | 87.44 | 158.7 | |
| Operating cash flow per share | -34.38 | 57.36 | -1.26 | 149.77 | -87.12 | |
| Free cash flow per share | -107.56 | -21.43 | -28.99 | 137.38 | -159.18 | |
| Cash per share | 228.69 | 347.89 | 313.59 | 432.89 | 604.61 | |
| Book value per share | 958.92 | 799.94 | 859.43 | 952.61 | 1.09K | |
| Tangible book value per share | 578.29 | 686.57 | 741.71 | 847.43 | 986.17 | |
| Share holders equity per share | 958.92 | 799.94 | 859.43 | 952.61 | 1.09K | |
| Interest debt per share | 6.78 | 51.49 | 53.07 | 52.56 | 315.8 | |
| Market cap | 376.63B | 1021.11B | 481.97B | 863.22B | 611.45B | |
| Enterprise value | 364.01B | 1005.52B | 468.34B | 845.35B | 602.49B | |
| P/E ratio | -9.61 | -80.52 | 110.87 | 164.68 | 64.27 | |
| Price to sales ratio | 14.95 | 36.02 | 14.84 | 22.87 | 12.01 | |
| POCF ratio | -187.63 | 299.89 | -6.38K | 96.15 | -117.09 | |
| PFCF ratio | -59.97 | -802.51 | -277.35 | 104.82 | -64.08 | |
| P/B Ratio | 6.73 | 21.5 | 9.36 | 15.12 | 9.36 | |
| PTB ratio | 6.73 | 21.5 | 9.36 | 15.12 | 9.36 | |
| EV to sales | 14.45 | 35.47 | 14.42 | 22.39 | 11.84 | |
| Enterprise value over EBITDA | -10.15 | -91.4 | 108.01 | 119.13 | 46.59 | |
| EV to operating cash flow | -181.34 | 295.31 | -6.2K | 94.16 | -115.37 | |
| EV to free cash flow | -57.96 | -790.26 | -269.51 | 102.65 | -63.14 | |
| Earnings yield | -0.1 | -0.01 | 0.01 | 0.01 | 0.02 | |
| Free cash flow yield | -0.02 | 0 | 0 | 0.01 | -0.02 | |
| Debt to equity | 0.01 | 0.06 | 0 | 0 | 0 | |
| Debt to assets | 0.12 | 0.2 | 0.19 | 0.18 | 0.32 | |
| Net debt to EBITDA | 0.35 | 1.42 | -3.14 | -2.52 | -0.69 | |
| Current ratio | 10.86 | 9.79 | 6.27 | 6.6 | 2.67 | |
| Interest coverage | 0 | 4.58 | 19.38 | 85.21 | 4.52 | |
| Income quality | 0.05 | -0.27 | -0.02 | 1.71 | -0.55 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Research and developement to revenue | 0.14 | 0.16 | 0.15 | 0.11 | 0.14 | |
| Intangibles to total assets | 0.35 | 0.11 | 0.11 | 0.09 | 0.07 | |
| Capex to operating cash flow | 2.13 | -1.37 | 22.02 | -0.08 | 0.83 | |
| Capex to revenue | -0.17 | -0.16 | -0.05 | -0.02 | -0.08 | |
| Capex to depreciation | -1.28 | -2.88 | -0.93 | -0.42 | -2.49 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.81K | 1.96K | 1.18K | 1.37K | 1.97K | |
| ROIC | -0.07 | 0 | 0.03 | 0.11 | 0.11 | |
| Return on tangible assets | -0.94 | -0.24 | 0.08 | 0.08 | 0.11 | |
| Graham Net | 142.4 | 197.31 | 186.25 | 274.92 | 237.34 | |
| Working capital | 23.47B | 29.21B | 29.13B | 36.43B | 41.58B | |
| Tangible asset value | 33.77B | 40.76B | 44.46B | 50.8B | 59.12B | |
| Net current asset value | 18.09B | 20.91B | 22.91B | 30.3B | 36.06B | |
| Invested capital | 0.01 | 0.06 | 0.06 | 0.05 | 0.26 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.35B | 1.52B | 1.29B | 1.97B | 1.4B | |
| Average inventory | 5.89B | 5.86B | 7.28B | 6.34B | 11.61B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 15.32 | 23.47 | 11.26 | 36.04 | 11.14 | |
| Days of inventory on hand | 115.91 | 118.57 | 154.37 | 115.83 | 224.7 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 23.83 | 15.55 | 32.41 | 10.13 | 32.75 | |
| Inventory turnover | 3.15 | 3.08 | 2.36 | 3.15 | 1.62 | |
| ROE | -0.7 | -0.27 | 0.08 | 0.09 | 0.15 | |
| Capex per share | -73.18 | -78.79 | -27.73 | -12.39 | -72.07 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 219.78 | 196.8 | 289.74 | 224.85 | 289.5 | |
| Net income per share | 59.64 | 31.2 | 82 | 37 | 65 | |
| Operating cash flow per share | 60.35 | -188.59 | 77.67 | -4.6 | 56.29 | |
| Free cash flow per share | 48.07 | -207.62 | 29.84 | -79.7 | -128.45 | |
| Cash per share | 815.79 | 604.61 | 636.18 | 586.72 | 477.38 | |
| Book value per share | 1.08K | 1.09K | 1.24K | 1.3K | 1.38K | |
| Tangible book value per share | 952.78 | 986.17 | 1.14K | 1.2K | 1.28K | |
| Share holders equity per share | 1.08K | 1.09K | 1.24K | 1.3K | 1.38K | |
| Interest debt per share | 287.52 | 300.38 | 313.13 | 294.85 | 316.93 | |
| Market cap | 890.2B | 782.3B | 682.37B | 694.27B | 614B | |
| Enterprise value | 867.79B | 773.33B | 672.24B | 692.05B | 619.67B | |
| P/E ratio | 62.24 | 104.57 | 34.6 | 77.7 | 39.62 | |
| Price to sales ratio | 67.57 | 66.31 | 39.17 | 51.14 | 35.58 | |
| POCF ratio | 246.07 | -69.2 | 146.13 | -2.5K | 182.98 | |
| PFCF ratio | 308.95 | -62.86 | 380.38 | -144.3 | -80.19 | |
| P/B Ratio | 13.75 | 11.97 | 9.14 | 8.83 | 7.44 | |
| PTB ratio | 13.75 | 11.97 | 9.14 | 8.83 | 7.44 | |
| EV to sales | 65.87 | 65.55 | 38.59 | 50.98 | 35.91 | |
| Enterprise value over EBITDA | 183.14 | 242.33 | 106.37 | 474.58 | 168.44 | |
| EV to operating cash flow | 239.88 | -68.41 | 143.96 | -2.49K | 184.66 | |
| EV to free cash flow | 301.18 | -62.13 | 374.73 | -143.83 | -80.93 | |
| Earnings yield | 0 | 0 | 0.01 | 0 | 0.01 | |
| Free cash flow yield | 0 | -0.02 | 0 | -0.01 | -0.01 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0.34 | 0.32 | 0.28 | 0.27 | 0.27 | |
| Net debt to EBITDA | -4.73 | -2.81 | -1.6 | -1.52 | 1.54 | |
| Current ratio | 2.58 | 2.67 | 3.07 | 3.07 | 2.67 | |
| Interest coverage | 4.47 | -0.77 | 6.61 | -1.77 | -3.71 | |
| Income quality | 1.01 | -6.04 | 0.95 | -0.12 | 0.87 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | |
| Research and developement to revenue | 0.09 | 0.3 | 0.09 | 0.13 | 0.08 | |
| Intangibles to total assets | 0.08 | 0.07 | 0.06 | 0.06 | 0.05 | |
| Capex to operating cash flow | -0.2 | 0.1 | -0.62 | 16.32 | -3.28 | |
| Capex to revenue | -0.06 | -0.1 | -0.17 | -0.33 | -0.64 | |
| Capex to depreciation | -1.83 | -2.03 | -4.45 | -21.2 | -18.04 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.2K | 874.79 | 1.51K | 1.04K | 1.42K | |
| ROIC | 0.05 | -0.01 | 0.06 | 0.02 | 0.03 | |
| Return on tangible assets | 0.04 | 0.02 | 0.05 | 0.02 | 0.04 | |
| Graham Net | 346.36 | 237.34 | 282.98 | 236.78 | 103.38 | |
| Working capital | 42.42B | 41.58B | 48.36B | 48.07B | 41.59B | |
| Tangible asset value | 57.12B | 59.12B | 68.47B | 72.39B | 76.29B | |
| Net current asset value | 36.23B | 36.06B | 42.77B | 42.31B | 35.69B | |
| Invested capital | 0.25 | 0.26 | 0.24 | 0.24 | 0.24 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 2B | 1.58B | 2.11B | 2.33B | 2.8B | |
| Average inventory | 12.82B | 16.32B | 15.54B | 15.74B | 16.35B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 21.98 | 12.14 | 18.53 | 25.86 | 26.38 | |
| Days of inventory on hand | 130.84 | 244.79 | 149.54 | 174.87 | 136.51 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 4.1 | 7.41 | 4.86 | 3.48 | 3.41 | |
| Inventory turnover | 0.69 | 0.37 | 0.6 | 0.51 | 0.66 | |
| ROE | 0.06 | 0.03 | 0.07 | 0.03 | 0.05 | |
| Capex per share | -12.28 | -19.03 | -47.83 | -75.1 | -184.74 |
005690.KS Frequently Asked Questions
What is Pharmicell Co., Ltd. stock symbol ?
Pharmicell Co., Ltd. is a KR stock and trading under the symbol 005690.KS
What is Pharmicell Co., Ltd. stock quote today ?
Pharmicell Co., Ltd. stock price is $10600 today.
Is Pharmicell Co., Ltd. stock public?
Yes, Pharmicell Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 450.05K
- Market Capitalization 622.24B
- CEO Hyun-Soo Kim
- Headquarters Seoul,KR
- IPO Date 2000-01-04
-
Website
https://www.pharmicell.com 
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.
